GO Main Menu Go Main Contents Go Bottom Menu
  • 24
    Top UK university hospital unveils data that suppo..
    CT-P10 also proven to have pharmacokinetic equivalence to reference rituximab ATLANTA-New data from University College London Hospitals NHS Foundation Trust (UCLH) on the safety and tolerability of rapid infusion of CT-P10 were present…
    2017-12-11
  • 23
    Celltrion Healthcare presents phase III switching ..
    6 November 2017.San Diego, California. New data presented at the 2017 American College of Rheumatology (ACR) Annual Meeting show that CT-P10 is comparable to reference rituximab in terms of efficacy, pharmacodynamics (PD) and safety profile, over a s…
    2017-11-05
  • 22
    Celltrion Healthcare present 1-year results for CT..
    CT-P13 shown to be comparable in efficacy and safety to reference infliximab in switched inflammatory bowel disease patients CT-P13 shown to be well-tolerated in subcutaneous form 30 October 2017, Barcelona, Spain.Today at the 25thUnited Europe…
    2017-10-30
  • 21
    Biosimilar trastuzumab candidate, CT-P6, shown to ..
    8 September 2017, Madrid, Spain -Celltrion Healthcare presents data at the European Society for Medical Oncology (ESMO) 2017 Congress thathighlights similarity in efficacy and safety between CT-P6 (biosimilar trastuzumab candidate) and reference tras…
    2017-09-08
  • 20
    Celltrion Healthcare: The Lancet Haematology publi..
    -Data show that CT-P10 is comparable to reference rituximab in terms of efficacy and safety The Lancet Haematologypublished detailed results from the ongoing phase 3,double-blind, randomised, parallel-group, active-controlled study of CT-P10.[1] …
    2017-07-13
  • 19
    Celltrion Healthcare: The Lancet Oncology publishe..
    Data show that CT-P6 is comparable to reference trastuzumab in terms of efficacy and safety Tuesday, June 14 2017.Detailed results from the phase 3,double-blind, randomised, parallel-group, active-controlled study of biosimilar trastuzumab candida…
    2017-06-14
  • 18
    Celltrion Healthcare showcases data supporting the..
    -Truxima® is non inferior to reference rituximab in advanced follicular lymphoma (FL) - a form of non-Hodgkin lymphoma ­ -Sustained efficacy was shown over 48 weeks irrespective of BMI in a phase III rheumatoid arthritis (RA) study that demon…
    2017-06-14
  • 17
    Biosimilar trastuzumab candidate, CT-P6, shown to ..
    4 June 2017, Chicago, USAData presented at the 2017 American Society of Clinical Oncology Annual Meeting has shown similarity in efficacy and safety between CT-P6 (biosimilar trastuzumab candidate) and reference trastuzumab as pre-operative (neoadjuv…
    2017-06-02
  • 16
    Celltrion Healthcare Launches Remsima® Monitor Kit..
    - Providing customized medical services for patients with autoimmune diseases by measuring serum drug concentration and anti-drug antibody production - 20~30% of the cost of existing therapeutic drug monitoring methods … Distinguishing Remsima®by ta…
    2017-04-03
  • 15
    Truxima™, the first biosimilar mAb in oncology, gr..
    22 February 2017, Incheon, South KoreaCelltrion Healthcare today announced that the European Commission has approved TruximaTM(biosimilar rituximab) for all indications of reference rituximab in the European Union (EU). Truxima™ is the first biosimil…
    2017-02-22